Weight loss

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity

Retrieved on: 
Thursday, May 2, 2024
Biometrics, Radiology, Biotechnology, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Liraglutide, Multimedia, Obesity, Drug development, Incidence, Patient, Weight loss, Dietary supplement

Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period.

Key Points: 
  • Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period.
  • Participants were also assessed for the exploratory outcome of adverse muscle composition, defined as high muscle fat infiltration and low muscle volume z-score.
  • The study found that liraglutide significantly reduced muscle fat infiltration when compared to placebo.
  • Additionally, a weight-invariant assessment of muscle volume was performed using AMRA’s muscle volume z-score did not show a significant reduction comparing liraglutide to placebo (mean treatment difference adjusted for baseline muscle volume z-score was -0.08 standard deviations).

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

Retrieved on: 
Thursday, May 2, 2024
Research, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Managed Care, Health, Science, Stanford University, Mortality, Heart, Fluid, Heart failure, ADHF, American College, Clinical trial, GDMT, AUC, Hospital, Weight loss, Partnership, Area studies, Nursing, Patient, Reprieve, Physician, Acute, Circulatory system, Kaiser Permanente, Hyperkalemia, SDOH, HF, Division, Hypotension, Pharmaceutical industry

Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.

Key Points: 
  • Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.
  • In the TREAT-AHF study, the distribution of inpatient body weight change was similar to those reported from ADHERE nearly two decades ago.
  • Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes.
  • The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Cencora Reports Fiscal 2024 Second Quarter Results

Retrieved on: 
Wednesday, May 1, 2024
General Health, Finance, Banking, Health, Professional Services, DEI, Table, EVP, Diabetes, Earnings per share, Weight loss, Doctor of Philosophy, Conference, Webcast, Newsweek, Culture, COVID-19, Doctor of Pharmacy, EPS, Interest expense, Share repurchase, Telephone, GAAP, Growth, Pharmaceutical industry

Diluted Earnings Per Share: Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease compared to $2.13 in the previous fiscal year’s second quarter.

Key Points: 
  • Diluted Earnings Per Share: Diluted earnings per share was $2.09 in the second quarter of fiscal 2024, a 1.9 percent decrease compared to $2.13 in the previous fiscal year’s second quarter.
  • Diluted Shares Outstanding: Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.
  • Adjusted Diluted Earnings Per Share: Adjusted diluted earnings per share was $3.80 in the second quarter of fiscal 2024, an 8.6 percent increase compared to $3.50 in the previous fiscal year’s second quarter.
  • Diluted weighted average shares outstanding for the second quarter of fiscal 2024 were 201.2 million, a decrease of 1.5 percent versus the prior fiscal year second quarter primarily as a result of share repurchases.

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
Monday, April 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Retrieved on: 
Tuesday, April 30, 2024
Contract research organization, American Diabetes Association, GAN, Part, Congress, EASL, Gubra, OXM, Weight loss, GCGR, GLP1R, GPR119, Obesity, SAD, Glucagon-like peptide-1 receptor, MASH, Pharmaceutical industry

"We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • "We have completed enrollment for Part 1 of our Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
  • DA-1726 has consistently shown, in our preclinical data, to sustain weight loss in diet-induced obese models by decreasing food consumption and boosting energy expenditure.
  • Both programs are progressing well, and we have been able to significantly accelerate the clinical timelines for DA-1726.
  • A member of the Dong-A ST Research Center will present pre-clinical data on DA-1726 in a poster presentation at this scientific session in Orlando, FL.

New Nextech Med Spa for Wellness and Weight Loss Software Increases Average Patient Encounter Revenue by 70%

Retrieved on: 
Wednesday, April 10, 2024
Massage, Health, Software, Wellness, Weight loss, Day, Beauty salon

"Med spas have been forced to choose between software built for massage spas or hair salons neither of which is right for a med spa,” said Nextech CEO Bill Lucchini.

Key Points: 
  • "Med spas have been forced to choose between software built for massage spas or hair salons neither of which is right for a med spa,” said Nextech CEO Bill Lucchini.
  • Now, we’ve made it easy to tap into the huge market for weight loss treatment."
  • Nextech Med Spa is a single solution with a full suite of tools providing med spa owners and staff with end-to-end visibility and management capabilities.
  • Based on average spend per patient visit of $536 as reported in the "The 2022 Medical Spa State of the Industry Report" by The American Medical Spa Association and on Nextech data.

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Retrieved on: 
Wednesday, April 10, 2024
Palmitoylethanolamide, Overweight, Therapy, Patent, Weight loss, Eating, Pharmaceutical industry

Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of  3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon) (“3-MMC”), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide (“PEA”).

Key Points: 
  • Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of  3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon) (“3-MMC”), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide (“PEA”).
  • “The field of weight loss has been a blockbuster of the pharmaceutical industry and generates billions of dollars to companies who are active in this space.
  • We at Clearmind have made it our goal to be at the forefront of developments in fields where we believe that we have an advantage over the marketed treatments, with weight loss being one of them.
  • The report authors say this increase could put a strain on healthcare systems and cause $4 trillion in economic damage.

Nourishing Tomorrow: How 'Food is Medicine' Advances Food Retailing and Positive Outcomes for Nutrition Responsive Health Conditions

Retrieved on: 
Friday, April 26, 2024
Software, General Health, Health, Supermarket, Technology, Food, Beverage, Fitness & Nutrition, Retail, Walmart, Summit, Health equity, Blood pressure, Instacart, Love, Tufts University, Partnership, Weight loss, Transport, Medicine, Science, PCP, Trust, Nutrition, Quality of life, Organization

At the Summit, Co-Founder and President of Good Measures, Stefany Shaheen, joined colleagues from Kroger, Instacart, Season Health, and Walmart on a panel titled "Research Advances in Food Retailing."

Key Points: 
  • At the Summit, Co-Founder and President of Good Measures, Stefany Shaheen, joined colleagues from Kroger, Instacart, Season Health, and Walmart on a panel titled "Research Advances in Food Retailing."
  • Together, they explored innovations in food retailing to advance the accessibility of food prescription programs and other approaches by offering programs in a personalized, culturally relevant manner.
  • Through our partnerships, we’re helping build personalized food prescription programs, tailored to individual health conditions," explained Sarah Mastrorocco, VP & GM of Instacart Health.
  • By prioritizing accessibility, cultural relevance, and nutrition intervention, these initiatives are not only improving health outcomes, but also empowering people to make healthier choices.

Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Online, Conditional sentence, Market, Semaglutide, Sale, Investment, Social media, Injection, Weight gain, Huadong Medicine, Safety, Risk, Plasma protein binding, CDC, Underweight, Alli, OTC, Overweight, Eli Lilly, GSK plc, Diabetes, Weight loss, Research, Liraglutide, USFDA, Appetite, Success, Roche, Obesity, Culture, Novo Nordisk, Distribution, Patient, Powder, Metabolism, Marketing, GIP, Cancer, COVID-19, Pharmacy, Growth, Prevalence, Pharmaceutical industry

The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.

Key Points: 
  • The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
  • The global weight loss drugs market is expected to grow at a CAGR of 49.85% over the years 2024-2029.
  • The weight loss drugs market in the Asia Pacific is expected to grow significantly during the forecasted period.
  • Offline distribution channels, comprising brick-and-mortar pharmacies, clinics, and healthcare facilities, dominated the global weight loss drugs market in 2023.